

Attorney Docket No.: 5904.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Malmlof et al.

Application No.: To be assigned Group Art Unit: To be assigned

Filed: February 5, 2004 Examiner: To be assigned

For: Use of a Growth Hormone or a Growth Hormone Secretagogue for Appetite-Suppression or Induction of Satiety

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of references were either cited by the Examiner or filed with USSN 10/140,512 filed May 2, 2002, the benefit of which is claimed under 35 USC 120.


The references are as follows:

1. U.S. Patent 5,597,797
2. U.S. Patent 5,912,229
3. U.S. Patent 5,952,301
4. U.S. Patent 5,998,463
5. U.S. Patent 6,191,160 B1
6. U.S. 2001/0011071 A1
7. WO 99/43705
8. EP 0 363 063 A2
9. Vasilatos-Younken et al., Domestic Animal Endocrinology, Vol. 17, pgs. 181-190 (1999)
10. William J. Klish, Acta Paediatrica Japonica, Vol. 37, pgs. 1-6 (1995)
11. Regina Vasilatos-Younken, J. Nutr. (Supplement), Vol. 125, pgs. 1783S-1789S (1995)
12. Wang et al., Journal of Endocrinology, Vol. 166, pgs. 621-630 (2000)
13. Dept. of medical Oncology, University of Newcastle upon Tyne. Glucagon. Online Medical Dictionary; <http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=glucagon>

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: February 5, 2004

Respectfully submitted,

Len S. Smith, Reg. No. 43,139
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449 (Rev. 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Atty. Docket No. 5904.214-US	Serial No. To be assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Malmlof et al.			
		Filing Date February 4, 2004?		Group To be assigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,597,797	1/97	Clark et al.	514	12	
		5,912,229	6/99	Thim et al.	514	12	
		5,952,301	9/99	Drucker	514	12	
		5,998,463	12/99	Hulin et al.	514	418	
		6,191,160 B1	2/01	Gao et al.	514	409	
		2001/0011071 A1	8/01	Knudsen et al.	514	12	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 99/43705	9/99	WO				
		EP 0363063 A2	4/90	EPO				
		.						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Vasilatos-Younken et al., Domestic Animal Endocrinology, Vol. 17, pgs. 181-190 (1999)
	William J. Klish, Acta Paediatrica Japonica, Vol. 37, pgs. 1-6 (1995)
	Regina Vasilatos-Younken, J. Nutr. (Supplement), Vol. 125, pgs. 1783S-1789S (1995)
	Wang et al., Journal of Endocrinology, Vol. 166, pgs. 621-630 (2000)
	Dept. of Medical Oncology, University of Newcastle upon Tyne. Glucagon. Online Medical Dictionary; http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=glucagon

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.